Skip to main content

REVIEW article

Front. Microbiol.
Sec. Infectious Agents and Disease
Volume 15 - 2024 | doi: 10.3389/fmicb.2024.1420226
This article is part of the Research Topic Recent advances in the prevention, diagnosis and treatment of Chagas Disease View all 5 articles

Recombinant proteins as promising antigens applied to the immunodiagnosis of Chagas Disease: a scoping review

Provisionally accepted
Alexsandro Galdino Alexsandro Galdino 1,2*Carlos Resende Carlos Resende 2Anna Ribeiro Anna Ribeiro 2Isadora Gandra Isadora Gandra 2Kamila Silva Kamila Silva 2Lucas Silva Lucas Silva 2Isabelle Barcelos Isabelle Barcelos 2Carolina Couto Carolina Couto 2Mariana Faria Mariana Faria 2Sabrina Pereira Sabrina Pereira 2Sandra Xavier Sandra Xavier 2Juliana Machado Juliana Machado 2Mariana Campos-da-Paz Mariana Campos-da-Paz 1Ana Thereza Chaves Ana Thereza Chaves 3Eduardo F. Coelho Eduardo F. Coelho 3Rodolfo C. Giunchetti Rodolfo C. Giunchetti 1Miguel Angel Chavez Fumagalli Miguel Angel Chavez Fumagalli 4Walderez O. Dutra Walderez O. Dutra 3Ana Alice M. Gonçalves Ana Alice M. Gonçalves 2
  • 1 Universidade Federal de São João del-Rei, São João del Rei, Brazil
  • 2 Microorganism Biotechnology Laboratory, Federal University São João Del-Rei, Divinópolis, Minas Gerais, Brazil
  • 3 Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  • 4 Catholic University of Santa María, Arequipa, Arequipa, Peru

The final, formatted version of the article will be published soon.

    Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is an important public health problem, occurring mainly in Latin America. The disease has a major social and economical effect, negatively impacting the life of the infected individuals, and bringing great costs to public health. An early and accurate diagnosis is essential for administration of early treatment. In addition, prognostic tests may aid disease management, decreasing hospitalization costs. However, the serological diagnostic scenario for CD still faces several challenges, making the development of new diagnostic kits a pressing matter. Facing this scenario, several researchers have expanded efforts in developing and testing new antigens, such as recombinant proteins and recombinant multiepitope proteins, with promising results. These recombinant antigens offer several advantages, such as improved sensitivity and specificity, in addition to facilitated scaling. Also, it has been possible to observe a rising number of studies using ELISA and point-of-care platforms, employing these antigens in the past few years. Among them, recombinant proteins were the most applied antigens, demonstrating great capacity to Excluído: promise 42 Excluído: .

    Keywords: Chagas disease1, Trypanosoma cruzi2, diagnosis3, Recombinant4, Serodiagnosis5, and 122 chronic serum samples

    Received: 19 Apr 2024; Accepted: 16 Jul 2024.

    Copyright: © 2024 Galdino, Resende, Ribeiro, Gandra, Silva, Silva, Barcelos, Couto, Faria, Pereira, Xavier, Machado, Campos-da-Paz, Chaves, Coelho, Giunchetti, Chavez Fumagalli, Dutra and Gonçalves. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Alexsandro Galdino, Universidade Federal de São João del-Rei, São João del Rei, Brazil

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.